The estimated Net Worth of Michael Sofinnova Venture P... is at least $37.9 Million dollars as of 11 August 2020. Michael P owns over 133,333 units of Checkmate Pharmaceuticals stock worth over $37,870,424 and over the last 4 years Michael sold CMPI stock worth over $0.
Sign up
Michael P CMPI stock SEC Form 4 insiders trading
Michael has made over 1 trades of the Checkmate Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Michael bought 133,333 units of CMPI stock worth $1,999,995 on 11 August 2020.
The largest trade Michael's ever made was buying 133,333 units of Checkmate Pharmaceuticals stock on 11 August 2020 worth over $1,999,995. On average, Michael trades about 133,333 units every 0 days since 2020. As of 11 August 2020 Michael still owns at least 3,606,707 units of Checkmate Pharmaceuticals stock.
You can see the complete history of Michael P stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Checkmate Pharmaceuticals
Over the last 4 years, insiders at Checkmate Pharmaceuticals have traded over $15,801,789 worth of Checkmate Pharmaceuticals stock and bought 928,470 units worth $13,457,615 . The most active insiders traders include Holdings A/S Novo, Global Strategic Fund Ii L.... und Michael Powell. On average, Checkmate Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $1,077,132. The most recent stock trade was executed by Global Strategic Fund Ii L.... on 13 May 2022, trading 131,650 units of CMPI stock currently worth $1,375,743.
What does Checkmate Pharmaceuticals do?
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Checkmate Pharmaceuticals's logo look like?
Complete history of Michael P stock trades at Checkmate Pharmaceuticals
Checkmate Pharmaceuticals executives and stock owners
Checkmate Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. James E. Wooldridge M.D.,
Chief Medical Officer -
Dr. Kleem Chaudhary Ph.D.,
Chief Bus. Officer -
Alan Fuhrman,
Interim CEO, Pres & Director -
Dr. Arthur M. Krieg,
Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director -
Katherine A. Eade,
Gen. Counsel -
Robert F. Dolski,
CFO & Principal Accounting Officer -
Arthur M Krieg,
Chief Scientific Officer -
Joy Yan,
Director -
Holdings A/S Novo,
10% owner -
Barry Labinger,
President and CEO -
Kleem Chaudhary,
Chief Business Officer -
Karen Brennan,
Chief Operating Officer -
Global Strategic Fund Ii L....,
-
Michael Sofinnova Venture P...,
-
Michael Powell,
Director -
Keith T. Flaherty,
Director -
Oren Isacoff,
Director -
Peter Colabuono,
Director -
Robert Dolski,
Chief Financial Officer -
Alan Fuhrman,
Director -
Jon Marc Wigginton,
Director -
Alan Bash,
Chief Executive Officer